From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Suvorexant or Belsomra (brand name) is an orexin receptor antagonist used to treat insomnia and improve sleep. Suvorexant acts as central nervous system depressant.[1][2]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Side effects of suvorexant include interaction with CYP3A inhibitors, increasing their effect.[1][3]

Costs and availability[edit | edit source]

Perscription only controlled drug. Generics not available.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Belsomra - FDA prescribing information, side effects and uses". Retrieved January 16, 2022.
  2. Holmberg, Monica (July 10, 2015). "Belsomra". Pharmacy Times. Retrieved January 15, 2022.
  3. Liu, Mei T. (April 13, 2020). "Current and Emerging Therapies for Insomnia". Am J Manag Care. 26 (4 Suppl): S85–S90.